Patents Assigned to GLORIANA THERAPEUTICS, INC.
  • Mammalian cell culture-produced neublastin antibodies
    Patent number: 10717965
    Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 21, 2020
    Assignee: Gloriana Therapeutics, Inc.
    Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
  • Mammalian cell culture-produced neublastin antibodies
    Patent number: 10669523
    Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 2, 2020
    Assignee: Gloriana Therapeutics, Inc.
    Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
  • Treatments for neurological disorders
    Patent number: 10328125
    Abstract: Disclosed are methods of improving impaired proprioception, treating brachial plexus injuries, regenerating large and small nerve fibers, treating dorsal root nerve injuries, and improving sensory neural responses in a subject by administration of a neublastin polypeptide.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: June 25, 2019
    Assignee: GLORIANA THERAPEUTICS, INC.
    Inventors: Anthony Rossomando, Frank Porreca, Dinah Wen-Yee Sah